# 2026-11996: Government Invents Better Alzheimer’s Drug Candidate

2026-11996, Government Owned Inventions Available for License: 4-Amino-2-(Piperidin-3-yl)Isoindoline-1,3-Diones as Anti-Inflammatory Agents for Systemic Degenerative and Neurodegenerative Disorders, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-06-15 (as of 2026-06-22).

- Canonical: https://policyrisk.com/federal-register/2026-11996
- As of: 2026-06-22
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-11996
- Title: Government Owned Inventions Available for License: 4-Amino-2-(Piperidin-3-yl)Isoindoline-1,3-Diones as Anti-Inflammatory Agents for Systemic Degenerative and Neurodegenerative Disorders
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 35992
- Published: 2026-06-15
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-22

## In one line

Government Invents Better Alzheimer’s Drug Candidate

## Summary

The National Institute on Aging has created new anti-inflammatory compounds that could help treat brain and body diseases like Alzheimer's and other degenerative disorders. These new drugs are safer, work better in the body, and avoid serious side effects seen in older medicines. Researchers and companies can now license these inventions to develop new treatments, potentially speeding up cures and improving lives.

## Abstract

The National Institute on Aging (NIA) seeks research co- development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic degenerative and neurodegenerative disorders.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20771](https://policyrisk.com/federal-register/2026-20771): Center for Scientific Review; Notice of Closed Meetings, 2026-10-09
- [2026-20705](https://policyrisk.com/federal-register/2026-20705): Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With…, 2026-10-09
- [2026-20424](https://policyrisk.com/federal-register/2026-20424): National Cancer Institute; Notice of Meeting, 2026-10-06
- [2026-20365](https://policyrisk.com/federal-register/2026-20365): Center For Scientific Review; Notice of Closed Meetings, 2026-10-05
- [2026-20151](https://policyrisk.com/federal-register/2026-20151): Notice of NIH Tribal Consultations and Listening Session, 2026-10-01
- [2026-19719](https://policyrisk.com/federal-register/2026-19719): Center for Scientific Review; Amended Notice of Meeting, 2026-09-28

## Sources
- [2026-11996 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/15/2026-11996/government-owned-inventions-available-for-license-4-amino-2-piperidin-3-ylisoindoline-13-diones-as)
- [2026-11996 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-15/pdf/2026-11996.pdf)

## Related
- [Previous: 2026-11995, Agency Information Collection Activities; Comment Request; Information Collecti…](https://policyrisk.com/federal-register/2026-11995)
- [Next: 2026-11997, Order Granting Temporary Exemptive Relief, Pursuant to Section 36(a)(1) of the…](https://policyrisk.com/federal-register/2026-11997)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-11996 (as of 2026-06-22).